1h Free Analyst Time
The RNA based therapeutics market is forecasted to grow by USD 1.26 billion during 2023-2028, accelerating at a CAGR of 5.54% during the forecast period. The report on the RNA based therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing investment and funding in RNA based therapeutics, expansion of RNA based therapeutics through government authorization, and rising incidence of chronic and infectious diseases.
The RNA based therapeutics market is segmented as below:
By Type
- mRNA therapeutics
- Antisense oligonucleotide (ASO) therapeutics
- RNA interference (RNAi) therapeutics
- Others
By Route Of Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Intramuscular (IM)
By Geographical Landscape
- Europe
- North America
- Asia
- Rest of World (ROW)
The report on the RNA based therapeutics market covers the following areas:
- RNA based therapeutics market sizing
- RNA based therapeutics market forecast
- RNA based therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Route of Administration
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global rna based therapeutics market: Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc., Ascidian Therapeutics Inc, AstraZeneca Plc, Beam Therapeutics Inc., Benitec Biopharma Inc., Biogen Inc., BioNTech SE, BioSpace, Circular Genomics Inc., CureVac AG, Esperovax, Gennova Biopharmaceuticals Ltd, Ionis Pharmaceuticals Inc., Moderna Inc., Novartis AG, Novo Nordisk AS, Omega Therapeutics Inc., Sarepta Therapeutics Inc., Silence Therapeutics plc, and Tevard Biosciences.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing collaborations and partnerships."
According to the report, one of the major drivers for this market is the growing investment and funding in rna based therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals Inc.
- Arbutus Biopharma Corp.
- Arcturus Therapeutics Holdings Inc.
- Arrowhead Pharmaceuticals Inc.
- Ascidian Therapeutics Inc
- AstraZeneca Plc
- Beam Therapeutics Inc.
- Benitec Biopharma Inc.
- Biogen Inc.
- BioNTech SE
- BioSpace
- Circular Genomics Inc.
- CureVac AG
- Esperovax
- Gennova Biopharmaceuticals Ltd
- Ionis Pharmaceuticals Inc.
- Moderna Inc.
- Novartis AG
- Novo Nordisk AS
- Omega Therapeutics Inc.
- Sarepta Therapeutics Inc.
- Silence Therapeutics plc
- Tevard Biosciences
